Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models

7Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In recent years, an increasing number of investigations has demonstrated the therapeutic potential of molecules targeting the endocannabinoid system. Cannabinoids of endogenous, phytogenic, and synthetic nature have been assessed in a wide variety of disease models ranging from neurological to metabolic disorders. Even though very few compounds of this type have already reached the market, numerous preclinical and clinical studies suggest that cannabinoids are suitable drugs for the clinical management of diverse pathologies. In this chapter, we will provide an overview of the endocannabinoid system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.

Cite

CITATION STYLE

APA

Morales, P., & Reggio, P. H. (2021). Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models. In Advances in Experimental Medicine and Biology (Vol. 1264, pp. 47–65). Springer. https://doi.org/10.1007/978-3-030-57369-0_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free